| Multidrug resistance proteins (MRPs) and cancer therapy YK Zhang, YJ Wang, P Gupta, ZS Chen The AAPS journal 17, 802-812, 2015 | 211 | 2015 |
| On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation BP Brown, YK Zhang, D Westover, Y Yan, H Qiao, V Huang, Z Du, ... Clinical Cancer Research 25 (11), 3341-3351, 2019 | 96 | 2019 |
| A novel potent anticancer compound optimized from a natural oridonin scaffold induces apoptosis and cell cycle arrest through the mitochondrial pathway S Xu, H Yao, S Luo, YK Zhang, DH Yang, D Li, G Wang, M Hu, Y Qiu, ... Journal of Medicinal Chemistry 60 (4), 1449-1468, 2017 | 96 | 2017 |
| Repositioning of tyrosine kinase inhibitors as antagonists of ATP-binding cassette transporters in anticancer drug resistance YJ Wang, YK Zhang, RJ Kathawala, ZS Chen Cancers 6 (4), 1925-1952, 2014 | 79 | 2014 |
| Lamellarin O, a Pyrrole Alkaloid from an Australian Marine Sponge, Ianthella sp., Reverses BCRP Mediated Drug Resistance in Cancer Cells XC Huang, X Xiao, YK Zhang, TT Talele, AA Salim, ZS Chen, RJ Capon Marine drugs 12 (7), 3818-3837, 2014 | 74 | 2014 |
| Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: in vitro and in vivo study YJ Wang, YK Zhang, GN Zhang, SB Al Rihani, MN Wei, P Gupta, ... Cancer letters 396, 145-154, 2017 | 67 | 2017 |
| Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters YK Zhang, GN Zhang, YJ Wang, BA Patel, TT Talele, DH Yang, ZS Chen Scientific reports 6 (1), 25694, 2016 | 65 | 2016 |
| In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1 H Zhang, A Patel, SL Ma, XJ Li, YK Zhang, PQ Yang, RJ Kathawala, ... British journal of pharmacology 171 (24), 5845-5857, 2014 | 65 | 2014 |
| Voruciclib, a potent CDK4/6 inhibitor, antagonizes ABCB1 and ABCG2-mediated multi-drug resistance in cancer cells P Gupta, YK Zhang, XY Zhang, YJ Wang, KW Lu, T Hall, R Peng, ... Cellular Physiology and Biochemistry 45 (4), 1515-1528, 2018 | 62 | 2018 |
| Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1 YJ Wang, RJ Kathawala, YK Zhang, A Patel, P Kumar, S Shukla, KL Fung, ... Biochemical pharmacology 90 (4), 367-378, 2014 | 61 | 2014 |
| The reversal of antineoplastic drug resistance in cancer cells by β-elemene GN Zhang, CR Ashby, YK Zhang, ZS Chen, H Guo Chinese journal of cancer 34, 1-8, 2015 | 58 | 2015 |
| β-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter HQ Guo, GN Zhang, YJ Wang, YK Zhang, K Sodani, TT Talele, CR Ashby, ... Oncology reports 31 (2), 858-866, 2014 | 58 | 2014 |
| Osimertinib (AZD9291), a mutant-selective EGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells XY Zhang, YK Zhang, YJ Wang, P Gupta, L Zeng, M Xu, XQ Wang, ... Molecules 21 (9), 1236, 2016 | 56 | 2016 |
| Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting Z Du, BP Brown, S Kim, D Ferguson, DC Pavlick, G Jayakumaran, ... Nature Communications 12 (1), 1382, 2021 | 55 | 2021 |
| Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: in vitro and in vivo GN Zhang, YK Zhang, YJ Wang, P Gupta, CR Ashby Jr, S Alqahtani, ... Cancer letters 424, 19-29, 2018 | 54 | 2018 |
| Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates S Xu, L Pei, C Wang, YK Zhang, D Li, H Yao, X Wu, ZS Chen, Y Sun, J Xu ACS medicinal chemistry letters 5 (7), 797-802, 2014 | 53 | 2014 |
| Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2 DS Wang, A Patel, S Shukla, YK Zhang, YJ Wang, RJ Kathawala, ... Oncotarget 5 (12), 4529, 2014 | 46 | 2014 |
| Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents YK Zhang, H Zhang, GN Zhang, YJ Wang, RJ Kathawala, R Si, BA Patel, ... Oncotarget 6 (27), 24277, 2015 | 44 | 2015 |
| The BTK inhibitor ibrutinib (PCI-32765) overcomes paclitaxel resistance in ABCB1-and ABCC10-overexpressing cells and tumors H Zhang, A Patel, YJ Wang, YK Zhang, RJ Kathawala, LH Qiu, BA Patel, ... Molecular cancer therapeutics 16 (6), 1021-1030, 2017 | 38 | 2017 |
| AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance H Zhang, YJ Wang, YK Zhang, DS Wang, RJ Kathawala, A Patel, ... Cancer letters 350 (1-2), 61-68, 2014 | 38 | 2014 |
Zhe-Sheng ChenCollege of Pharmacy and Health Sciences, St. John's University在 stjohns.edu 的电子邮件经过验证
